Control of cell proliferation by Polycomb group proteins (PcG) is an important facet of cellular homeostasis and its disruption can promote tumorigenesis. We recently described CBX7 as a novel PcG protein controlling the growth of normal cells. In an attempt to identify a putative role of CBX7 in tumorigenesis, we analysed CBX7 expression in a panel of cancer cell lines and primary tissues. CBX7 was highly expressed in three different prostate cancer cell lines and present at elevated levels in normal prostate. Ablation of CBX7 expression using short hairpin RNAs (shRNA) resulted in upregulation of p16 Ink4a and p14
Control of cell proliferation by Polycomb group proteins (PcG) is an important facet of cellular homeostasis and its disruption can promote tumorigenesis. We recently described CBX7 as a novel PcG protein controlling the growth of normal cells. In an attempt to identify a putative role of CBX7 in tumorigenesis, we analysed CBX7 expression in a panel of cancer cell lines and primary tissues. CBX7 was highly expressed in three different prostate cancer cell lines and present at elevated levels in normal prostate. Ablation of CBX7 expression using short hairpin RNAs (shRNA) resulted in upregulation of p16 Ink4a and p14
Arf in both LNCaP and PC-3 prostate cell lines. CBX7 knockdown caused an impairment of cell growth that was dependent on the status of the p14 Arf /p53 and p16 Ink4a /Rb pathways in both normal and cancer prostate cells. CBX7 overexpression in LNCaP cells resulted in a slight growth advantage in both androgen-dependent andindependent conditions. Moreover, CBX7 expression cooperated with c-Myc in rendering LNCaP cells insensitive to growth arrest by androgen receptor inhibition. Together, these data suggest that CBX7 represses p16
Ink4a and p14 Arf expression in normal and tumor-derived prostate cells, affecting their growth depending on the status of the p16 Ink4a /Rb and the p14
Introduction
Cancer is a progressive disease in which tumor cells acquire different characteristics in a stepwise manner in order to evolve to more malignant stages. For example, cells have to be able to overcome antiproliferative signals, become growth factor independent or acquire unlimited proliferative abilities for a tumor to be able to survive and grow. Most of these alterations can be traced to discrete genetic events, such as mutations, amplifications or deletions of specific genes (Hanahan and Weinberg, 2000; Futreal et al., 2004) . However, it is becoming increasingly apparent that epigenetic changes are also responsible for the acquisition of tumorigenic phenotypes (Baylin and Herman, 2000; Jacobs and van Lohuizen, 2002; Jones, 2002; Pasini et al., 2004) . Epigenetic modifications involve two main systems, one triggering DNA methylation and the other causing different histone modifications. Such epigenetic modifications act as a cellular memory that can preserve the transcriptional status of genes through multiple cell divisions (Francis and Kingston, 2001) . As a consequence, the perturbation of this transcriptional memory can lead to severe developmental defects, and also to malignancy (Muyrers-Chen and Paro, 2001) . Polycomb group genes (PcG) are a set of structurally diverse but functionally epistatic genes linking histone modifications with transcriptional repression (Otte and Kwaks, 2003; Lund and van Lohuizen, 2004) . Biochemical and genetic studies indicate that PcG proteins act as part of at least two distinct high molecular weight complexes referred to as Polycomb repressive complexes 1 and 2 (PRC1 and PRC2) (Lund and van Lohuizen, 2004; Wang et al., 2004) . In mammalian cells, Enhancer of Zeste (EZH2), Early embryonic deficient (EED), Suppressor of Zeste (SUZ12) and other associated proteins form the PRC2. The PRC2 complex has associated histone deacetylase and histone methyl transferase (specific for lysine 27 (K27) of Histone H3) activities, thus contributing to the establishment of histone repressive marks (Kuzmichev et al., 2002; Kirmizis et al., 2004) . On the other hand, the core components of the PRC1 complex are the mammalian homologs of Drosophila Polycomb (Pc), Posterior sex combs (Psc), Sex combs extra (Sce) and Polyhomeiotic (Ph). The PRC1 complex can recognize and bind to trimethylated K27 of Histone H3 through Pc proteins, and contributes to gene repression by inhibiting transcription initiation (Cao et al., 2002) .
Several studies have highlighted the deregulation of different PcG proteins in tumorigenesis. For example, Bmi-1 is amplified in blood malignancies and medulloblastomas (Raaphorst et al., 2000; Bea et al., 2001; van Kemenade et al., 2001; Lessard and Sauvageau, 2003) . EZH2 is also involved in blood malignancies (Raaphorst et al., 2000; Visser et al., 2001) , and interestingly its expression is increased in metastatic stages of both prostate and breast tumors (Varambally et al., 2002; Kleer et al., 2003) . The link between other PcG genes and cancer is less well established. Mel18 has been suggested to act as a tumor suppressor gene (Kanno et al., 1995) , Rae28/Ph1 alterations are observed in acute lymphoblastic leukemia (Tokimasa et al., 2001) and SUZ12 is upregulated in colon tumors (Kirmizis et al., 2003) . As regards Pc genes, no specific data exist although Pc2/CBX4 is considered a putative tumor suppressor (Satijn et al., 1997) . Up to five Pc homologs have been characterized or are predicted to exist in humans (Pc1/M33/CBX2, Pc2/CBX4, Pc3/CBX8, CBX6 and CBX7). Recently, we identified CBX7 in a functional genetic screen to isolate genes that can extend the lifespan of primary human prostate epithelial cells (Gil et al., 2004) . CBX7 is unique among the Pc family in its ability to immortalize mouse embryonic fibroblasts (MEF) and to extend the lifespan of a number of different human primary cells.
Prostate cancer is one of the leading causes of male mortality in western countries, and its incidence is increasing as a consequence of population aging (Nelson et al., 2003) . Substantial efforts have been made to identify prognostic markers that distinguish different stages of the disease. However, relatively little is known about the genetic and molecular alterations that drive prostate cancer tumorigenesis. A better understanding of the genetic events involved in prostate cancer progression, and the pathways necessary for sustaining normal and malignant prostate growth will be important for the establishment of specific therapies targeting different aspects of the illness (Abate-Shen and Shen, 2000; Visakorpi, 2003; Porkka and Visakorpi, 2004) .
To address the potential contribution of CBX7 to cancer, we first screened CBX7 expression levels in a large set of human tissue samples and cancer cell lines. Owing to the high expression of CBX7 in both normal prostate tissue and in the prostate cancer cell lines tested, we decided to further analyse the ability of CBX7 to regulate the growth of normal and cancer cells.
Results

CBX7 is expressed in normal prostate and prostate cancer cell lines
In order to discern physiological circumstances in which CBX7 might regulate cell growth, we analysed CBX7 expression in a TA73 tissue microarray (TMA) of 32 normal human tissues (Table 1 ) and in a panel of cancer cell lines (Figure 1 ). Immunohistochemical staining detected CBX7 expression at medium or high levels in five tissues on the TMA, including the thyroid and parathyroid glands, fallopian tube, gallbladder and prostate (Table 1 ). There was no detectable expression in nearly half of the assayed samples (15 tissues) and only low levels in a further 11 tissues. Further analysis showed that CBX7 was expressed in the basal cells and in the luminal secretory cells of normal prostate (Figure 1a) . CBX7 was expressed to even higher levels in prostatic intraepithelial neoplasia (PIN) (Figure 1b ) and its expression was also detected in some prostate carcinoma (PCa) samples (Figure 1c and d) . The specificity of the staining was confirmed by using a blocking peptide or (compare panels 1d and e) or by omitting the primary antibody (data not shown). CBX7 was clearly nuclear, and it appeared less intense in PCa samples than in nonmalignant prostate. The percentage of tumors expressing CBX7 was higher in untreated than in hormone-refractory PCa samples (summarized in Table 2 ), but the difference was not statistically significant (P ¼ 0.2190, Fisher's exact test). We could neither find a correlation between CBX7 expression and Gleason score, but overall we can state that CBX7 was expressed in 20-30% of both untreated and hormonerefractory PCa.
We next analysed CBX7 mRNA levels in 27 human cancer cell lines from different origins. In addition to (Figure 1f , asterisks). The highest levels of CBX7 were observed in the PC-3 and DU-145 cell lines, both of which are androgen-independent, whereas lower levels were observed in the androgen-dependent line LNCaP ( Figure 1f ).
CBX7 is required for growth of normal and cancer prostate cells
The levels of CBX7 expression in prostate cancer cell lines and in normal human prostate prompted us to study the role of CBX7 in the proliferation of these cells. We have previously shown that knocking down CBX7 expression with an appropriate short hairpin RNA can impair the growth of HPrEC cells ( Figure 2a , Gil et al., 2004) . Two of the three shRNA tested caused a substantial reduction in CBX7 levels on WI-38 cells (data not shown) and had similar phenotypic consequences on cell proliferation (Supplementary Figure  1A) . Specificity was confirmed by the ability of mouse Cbx7 to over-ride the effects of shRNA directed against the human sequence, and by the absence of any effect in cell lines lacking CBX7 (Supplementary Figure 1B) . Cultures of primary HPrEC are heterogeneous, composed of colonies founded by cells with different (Hudson et al., 2000) . Although CBX7 ablation caused a significant reduction in the number of type I colonies, the effects on the type II colonies, which have a higher proliferative potential, appeared to be more dramatic (data not shown).
To extend these analyses, we also introduced CBX7 shRNA into the three prostate cancer cell lines identified in Figure 1c . Whereas CBX7 shRNA induced growth arrest in LNCaP cells, it caused more modest growth impairment in PC-3 cells and we did not observe an effect in DU-145 cells (Figure 2b ). Flow cytometric analysis showed that the inhibition of LNCaP cells proliferation was due primarily to a cell cycle arrest on G1-phase and not to an increase in apoptosis (Figure 2c) . A similar profile was observed, and similar conclusions can be drawn in PC-3 cells (data not shown).
CBX7 controls cell growth by repressing p14
Arf and p16
Ink4a expression
Ectopic expression of CBX7 extends the lifespan of human primary cells by repressing p16 Ink4a and immortalizes MEF by repressing p19
Arf and p16 Ink4a (Gil et al., 2004) . In order to understand why CBX7 shRNA had a different impact on the proliferation of the different prostate cell lines analysed, despite knocking down CBX7 to a similar extent (Figure 3a) , we studied its effects on the levels of proteins located on the p14
Arf /p53 and p16 Ink4a /Rb pathways. Reduction of CBX7 in LNCaP cells caused an increase in p14
Ink4a mRNA levels as judged by RT-PCR (data not shown) These effects were reproduced at the protein level ( Figure 3b ) and were accompanied by the upregulation of p53 and p21
Cip1
, and the reduced phosphorylation of pRb (Figure 3b ). These are the predicted consequences of p14
Arf -mediated stabilization of p53 and p16
Ink4a -mediated inhibition of Cdk4 and Cdk6, and would be consistent with the observed G1 arrest. Although shRNA against CBX7 similarly increased p14
Ink4a protein levels in PC-3 cells, with subsequent effects on pRb phosphorylation, these cells lack p53 (Carroll et al., 1993) and consequently an increase in p21
Cip1 levels is not observed (Figure 3c ). DU-145 cells, which are insensitive to the effects of CBX7 shRNA, are also p53 negative and lack functional Rb (Chi et al., 1997) .
To further investigate the extent to which p53 and pRb status influences the response to CBX7 knockdown, we used the HPV E6 protein to inhibit p53 function and HPV E7 to inhibit pRb in the prostate cancer cell lines. The shRNA against CBX7 still slowed the growth of LNCaP/E6 and LNCaP/E7 cells but to a lesser extent than in the control LNCaP/GFP cells, whereas expression of both E6 and E7 largely avoided the deleterious effects of ablating CBX7 (Figure 3d ). In PC-3 cells (p53-null), E7 expression was sufficient to render cells insensitive to the effects of the shRNA against CBX7 (Figure 3e ). These results suggest that the extent to which CBX7 ablation affects cell proliferation is dictated by the functional status of the p14
Arf /p53 and p16 Ink4a /Rb pathways.
CBX7 synergizes with c-Myc in the conversion to androgen independence of LNCaP cells
The molecular mechanisms involved in the transition from androgen-dependence (AD) to independence (AI) in the late stages of prostate cancer and/or during antihormonal treatment are still largely unknown (Feldman and Feldman, 2001) . To explore a possible link between CBX7 and AI, we asked whether CBX7 could suppress the accumulation of p16
Ink4a that occurs when LNCaP cells are treated with the AR inhibitor bicalutamide (Lu et al., 1997; Bernard et al., 2003) . In control cells infected with the GFP vector (LNCaP/ GFP), bicalutamide caused a significant increase in the endogenous p16
Ink4a protein levels (Figure 4a ). In cells expressing CBX7, both the basal and induced levels of p16
Ink4a were substantially reduced (Figure 4a ). Thus, CBX7 effectively neutralized the effects of bicalutamide on p16
Ink4a
. However, although ectopic CBX7 conferred a growth advantage on untreated LNCaP cells, similar to that achieved by introduction of HPV E6 and E7, it did not override the long-term growth arrest observed Arf and p16 Ink4a , Rb, p21 Cip1 , p53 and actin as a loading control. An extra lane with cell extracts from LNCaP cells (C þ ) was included in the PC-3 p53 Western blot as a control of p53 reactivity as PC-3 cells lack p53 expression. (d) Expression of E6 and E7 overcome CBX7 depletion in LNCaP cells. LNCaP cells ectopically expressing E6, E7, both or GFP as control were infected with pRS or pRS/CBX7, selected and later seeded at low density in 10-cm dishes. After 12 days, the cells were fixed, stained and the relative cell number was quantified. The results are normalized to 100% for each cell line infected with the pRS vector. (e) E7 expression overcome CBX7 depletion in PC-3 cells. PC-3 cells ectopically expressing E7 or GFP as control were infected with pRS or pRS/CBX7 in 10-cm dishes. After selection, the PC-3 cells were seeded and cultured during 10 days. After which, the cells were fixed, stained and the relative cell number was quantified in each case CBX7 controls prostate cells growth D Bernard et al following treatment with bicalutamide ( Figure 4b ) in accordance with the pleiotropic effects caused by androgen receptor inhibition (Bernard et al., 2003) .
In contrast, we and others have shown that c-Myc can override bicalutamide-mediated arrest and it is involved in AI progression during prostate cancer (Visakorpi et al., 1995; Nupponen et al., 1998; Bernard et al., 2003) . We therefore asked whether the ability of CBX7 to suppress p16
Ink4a and p14 Arf might cooperate with c-Myc as, in other cell contexts, c-Myc has been shown to induce the expression of both p16
Ink4a and p14 Arf (Zindy et al., 1998; Drayton et al., 2003) . Accordingly, in LNCaP cells, introduction of c-Myc resulted in the accumulation of p14
Arf and consequent upregulation of p53 (Figure 5a ). The effect on p14
Arf was largely suppressed in cells expressing CBX7 (Figure 5b ). Consistent with these effects, CBX7 appeared to enhance the ability of c-Myc to promote growth of LNCaP cells both in the absence and presence of the androgen receptor inhibitor (Figure 5c ).
Discussion
Prostate cancer is one of the major malignancies affecting elderly men of western background. Owing to this, a deeper understanding of the genetic alterations involved in prostate tumorigenesis is urgently required as a first step towards more effective diagnosis, prognosis and treatment. In this report, we have focused on the Pc protein, CBX7, which was recently identified through its ability to extend the lifespan of HPrEC and other primary cell types (Gil et al., 2004) . As this attribute could contribute to tumorigenesis, we undertook a survey of CBX7 expression, using IHC to detect the protein in normal human tissues and RT-PCR to detect the RNA in a panel of human cancer cell lines. The profile of CBX7 expression seemed quite restricted, as the majority of the normal human tissues examined by IHC were either negative for CBX7 expression or had relatively low levels. Although there was no a priori reason to connect CBX7 with prostate cells, we observed significant expression in normal prostate samples, in PIN, and in the three prostate cancer cell lines included in the study. This expression pattern is intriguing but given the limitations of this initial survey, it does not exclude a significant role for CBX7 in additional tissues.
To try to substantiate the link between CBX7 and prostate, we showed that shRNA knock down of CBX7 impaired the growth of normal prostate cells in tissue culture. In prostate cancer cell lines, the impact of CBX7 ablation was dependent on the genetic status of the cells. Thus, CBX7 silencing had no effect on the growth of DU-145 cells, in which both the p53 and p16/pRb pathways are defective, an intermediate effect on PC-3 cells, which are p53 null, and it had the strongest effect on LNCaP cells, in which both pathways are intact. Accordingly, depending on the background, the growth inhibitory effects of CBX7 shRNA could be overcome by the selective or simultaneous interference with the p53 and pRb pathways by HPV E6 and E7, respectively.
At face value, therefore, our data imply that the repression of the p16
Ink4a and p14 Arf tumor suppressors by CBX7 is required for the growth of normal prostate and some prostate cancer cells. Although genetic analysis favours this interpretation (Figure 3d and e) and CBX7 is similarly knocked down by the shRNA in both cell lines (Figure 3a) , we cannot exclude the possibility that other factors contribute to the different phenotypes observed. In addition, it should be acknowledged that these findings may specifically relate to growth in tissue culture and the inevitable activation the p14
Arf /p53 and p16
Ink4a
/Rb pathways that occur in this context. It will be important to establish whether Cbx7 ablation in vivo provides similar indications.
As prostate tumors rely heavily on androgens to proliferate, androgen ablation is used as a major therapeutic strategy to fight this disease. Although highly efficient, one side effect of this therapy is the Ink4a accumulation in cells with or without androgen. Cells were treated every 2 days with bicalutamide. After 7 days, total cell extracts were prepared, separated by SDS-PAGE and analysed by immunoblotting against p16
Ink4a , CBX7 and actin as a loading control. (b) Effect of CBX7 on LNCaP cells growth with or without AR stimulation. LNCaP cells ectopically expressing E6, CBX7 or GFP were seeded in 10-cm dishes and cultured with or without bicalutamide. After 12 days, the cells were fixed, stained and the relative cell number was quantified. The results are normalized to the growth of control LNCaP cells without AR stimulation. The percentages refer to the growth percentage of cells without AR stimulation compared to the same one with AR stimulation CBX7 controls prostate cells growth D Bernard et al appearance of recurrent tumors that are androgenindependent, more aggressive in their growth dynamics and unresponsive to the currently available treatments. Thus, understanding and deciphering the genetic events involved in the transition from androgen-dependence to androgen-independence is important (Feldman and Feldman, 2001 ). Constitutive CBX7 expression in an androgen-dependent cell line conferred a growth advantage in androgen-stimulated conditions but had little effect over cell growth in androgen-depleted conditions despite the reduced accumulation of p16
. Nevertheless, CBX7 was found to cooperate with the protooncogene c-Myc in inducing androgen-independent cell growth. However, the possibility of CBX7 affecting AI progression must be viewed with caution, as we did not observed increased expression of CBX7 when comparing hormone-refractory and untreated tumors. The ability of CBX7 to cooperate with c-Myc has also been noted in cell transformation assays in MEF and in an in vivo lymphomagenesis model (Scott CL, Gil J, Peters G, Beach D and Lowe SW, manuscript in preparation).
It is clear that chromatin modifications have an important role in cancer. In addition to the silencing of specific genes by methylation, other epigenetic modifications, such as gene silencing triggered by PcG proteins, have been shown to be involved in specific tumor types. For example, EZH2, another PcG protein, has been clearly implicated in the progression of prostate cancer (Varambally et al., 2002) . Genetic analyses suggest that transcriptional repression of target gene/s by EZH2 is involved in the process (Varambally et al., 2002; Bracken et al., 2003; Kleer et al., 2003) , but the Ink4a/Arf locus does not seem to play a pivotal role (Bracken et al., 2003) . In contrast, the Psc homolog, Bmi1, has clearly been shown to repress Ink4a/Arf and is overexpressed in specific types of lymphoma, medulloblastomas, and mammary tumors (Raaphorst et al., 2000; Bea et al., 2001; van Kemenade et al., 2001; Lessard and Sauvageau, 2003) . Here we provide the first evidence that CBX7 dysregulation might also contribute to the behavior of prostate tumor cells through repression of the Ink4a/Arf locus. However, the immunohistochemical staining suggested that the high CBX7 expression observed in normal prostate epithelial cells and intraepithelial neoplasia was sustained in only 22% of the prostate cancer specimens analysed. Thus, it seems that CBX7 overexpression is not an essential event during prostate cancer progression, although more extensive studies are clearly called for.
In summary, CBX7 expression is high in both prostate tissue and prostate cancer cell lines, and CBX7 has a role in maintaining prostate cell growth in normal prostate, in prostate cancer cells, and it also cooperates with c-Myc in androgen-independent conversion. Our results emphasize the role of epigenetic mechanisms, beside or in addition to genetic mechanisms, to trigger cell proliferation in both physiological and pathological conditions.
Materials and methods
Cell culture and retroviral-mediated gene transfer
LNCaP, PC-3 and DU-145 cells (obtained from the ATCC) were cultured in RPMI 1640 (GibcoBRL) supplemented with 10% FCS (Sigma) and glutamine (GibcoBRL). HPrECs were derived from the histologically normal prostate of patients undergoing cystectomy for bladder carcinoma. Briefly, the tissue was minced and digested in RPMI 1640 medium containing 5% FCS and 400 U of collagenase per ml (Hudson et al., 2000) . Following separation from stromal cells, epithelial acini were dissociated in trypsin to produce a single cell suspension. Cells were plated in collagen-coated plates and maintained in PrEGM (Biowhittaker) serum-free medium according to the manufacturer's instructions. For the analysis of the clonal distribution of primary prostate culture, cells were seeded at either 10 3 , 2 Â 10 3 or 10 4 cells on a feeder layer of irradiated 3T3 cells. Cells were infected with the appropriate short hairpin RNAs (shRNA) encoding retroviruses on day 5 after seeding, and colonies scored on days 15-21.
The packaging cell line 293GP (Clontech) was grown in DMEM supplemented with 10% FCS. Retrovirus production and infection of target cells was performed according to Wang et al. (1998) . The retroviral vectors used were: pHygroMarX IV / eGFP, pHygroMarX II /mCBX7, LXSN/E6, LXSN/E7, LXSN/ E6E7 and pHygroMarX II /c-myc. The retroviral vector used for shRNA against CBX7 has been already described (Gil et al., 2004) .
Growth curves, colony formation assays and cell cycle analysis
LNCaP and PC-3 cells were infected with pRS or pRS/CBX7 retroviral vectors in 10-cm dishes. For the colony formation assays, we infected 4 Â 10 5 LNCaP with the pRS or pRS/CBX7 vectors. After 2 days, the cells were cultured in the presence of 100 ng/ml of puromycin for 12 further days before fixing. After infection and selection, 3 Â 10 5 PC-3 or DU-145 cells were seeded in 10-cm dishes and fixed 10 days later. Dishes were stained with crystal violet as described above. For cell cycle analysis, the cells were manipulated as for the colony formation assays. They were fixed in ice-cold 70% ethanol, washed in PBS and treated with 10 mg/ml RNaseA for 30 min at 371C. Propidium iodide (Sigma) at 10 mg/ml was added to the samples prior to analysis on the FACSCalibur (Becton Dickinson).
Tissue microarray immunohistochemistry
The expression of CBX7 was first analysed using the TA73 tissue microarray (TMA) produced in the Immunohistochemistry Unit of the CNIO. This TMA is composed of 40 duplicated normal tissue samples from autopsies. All the tissues had been fixed in 4% formalin and paraffin-embedded according to routine procedures. Tissue (3 mm) sections from the TMA blocks were sectioned and applied to special immunohistochemistry-coated slides (DAKO, Glostrup, Denmark). The slides were baked overnight in a 561C oven. Sections were deparaffinized in xylene for 20 min, rehydrated through a graded ethanol series and washed with PBS. Antigen retrieval was achieved by a 2-min heat treatment in a pressure cooker, containing 1 l of preboiled 10 mM sodium citrate buffer, (pH 6.5, DAKO). Endogenous peroxidase activity was quenched by treatment with 1.5% hydrogen peroxide (DAKO) in methanol for 10 min. After incubation with anti-CBX7 antibody (Gil et al., 2004 ) at a 1 : 1250 dilution, immunodetection was performed with the LSAB Visualization System (DAKO) using 3,3 0 -diaminobenzidine chromogen as substrate, according to the manufacturer's instructions. Hematoxylin was used for counterstaining (DAKO). All the procedures were performed using the Techmate 500 automated system (Dako Cytomation, Glostrup, Denmark).
Next, a TMA containing 38 untreated prostate and 62 hormone-refractory prostate carcinomas obtained from Tampere University Hospital was stained. The untreated tumor samples were obtained from prostatectomy specimens, whereas the hormone-refractory tumor samples were obtained from transurethral resections of prostate (TURP) from patients experiencing urethral obstruction despite ongoing hormonal therapy. The mean time from beginning of hormonal therapy to progression (TURP) was 31 months (range: 1-122). To improve the staining, 2 min incubation in Citra-solution (BioGenex, SanRamon, CA, USA), using an autoclave was performed. CBX7 staining (Gil et al., 2004) was visualized with a horseradish peroxidase-conjugated secondary antibody and using diaminobenzidine as a chromogen (PowerVision, ImmunoVision Inc.). Sections were counterstained with haematoxylin. The staining intensity was scored as no staining (0), faint staining (1 þ ), moderate staining (2 þ ) or strong staining (3 þ ).
Western blot analyses
Western blots were carried out using RIPA whole-cell extracts, separated on 8-12.5% SDS-PAGE gels, and transferred to nitrocellulose membranes (Amersham). Membranes were incubated with the following primary antibodies: anti-CBX7 (Gil et al., 2004) , anti-c-Myc (sc-764, Santa Cruz Biotechnology), anti-p16
Ink4a (sc-468, Santa Cruz Biotechnology), anti-Rb (554136, Pharmingen), anti-b-actin (A5316, Sigma), anti-p53 (sc-126, Santa Cruz Biotechnology), anti-p21 (sc-397, Santa Cruz Biotechnology) and anti-p14
Arf (sc-8613, Santa Cruz Biotechnology). The corresponding peroxidase-labeled secondary antibody (Santa Cruz Biotechnology) was detected using ECL Western blotting reagents (Amersham Biosciences).
RT-PCR
Cells were homogenized in Trizol (Invitrogen) or Tri Reagent kit (Molecular Research Center Inc.), and total RNA was isolated according to the manufacturer's recommendations. Complementary DNAs were synthesized using the first-strand cDNA synthesis kit (Roche) and amplified in a final volume of 50 ml containing 150 mM dNTP, 2 mM MgCl 2 , 1 U of Taq gold polymerase (Applied Biosystems), and each primer at 1 mM.
For p14
Arf , DMSO was added at a final concentration of 1%. Primers used were as follows: p14
Arf forward, GAGTGG CGCTGCTCACCTC; p14
Arf reverse, TACCGTGCGACAT CGCGAT; p16 Ink4a forward, CATAGATGCCGCGGAA GGT; p16
Ink4a reverse, CCCGAGGTTTCTCAGAGCCT and b-actin as described elsewhere (Kasibhatla et al., 1998) . In all, 25-30 amplification cycles were performed at 941C for 1 min; 551C for 1 min and 721C for 1 min, with an initial denaturation step of 5 min at 951C. For CBX7 detection in the panel of cell lines, we used the primers CBX7Fw (5 0 -AAAGTCGAG TATCTGGTGAAGTGG-3 0 ), and CBX7Rv (5 0 -GCTCCCG TCGATGGCTGTGG-3 0 ), and the program consisted of 30 cycles: 941C, 30 s denaturation; 571C, 30 s annealing and 721C, 2 min extension.
